Our work provides the evidence that LY500307, a synthetic ERβ agonist has potential to specifically reduce the proliferation of GBM cells with high potency, induce apoptosis, promote G2/M cell cycle arrest and sensitize GBM cells to chemotherapeutic agents. Here, ESR2 is linked to glioblastoma.